# A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

> **NCT03479307** · PHASE3 · COMPLETED · sponsor: **Faes Farma, S.A.** · enrollment: 228 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Bilastine Ophthalmic Solution 0.6%
- **DRUG:** Ketotifen Ophthalmic Solution 0.025% (Zaditen)
- **DRUG:** Vehicle of Bilastine Ophthalmic Solution

## Key facts

- **NCT ID:** NCT03479307
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-07
- **Primary completion:** 2018-08-09
- **Final completion:** 2018-08-10
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2023-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03479307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03479307, "A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03479307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*